On Tuesday, March 25, the Office of Information Technology will upgrade the GlobalProtect VPN client.

A service disruption on campus brought down many University services and applications for much of Thursday, though the issue ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

For community members who currently rely on SMS messages or phone calls for multi-factor authentication (MFA), OIT instructs ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

The study suggests that omalizumab could become a safer, more effective alternative to OIT for people with highly sensitive ...

The high rate of allergic reactions and other intolerable side effects of oral immunotherapy in the NIH-funded trial ...